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Accepted 27 June 2012AbstractObjective: The aim of this study was to compare the changes in urinary symptoms and urodynamic parameters after administration of tolterodine
in women with an overactive bladder (OAB).
Materials and Methods: Thirty-eight women diagnosed with OAB and treated with tolterodine were reviewed. Urinalysis, pelvic examination, 3-
day bladder diary, urodynamic study, and a personal interview to identify urinary symptoms prior to and 3 months after treatment were recorded
and interpreted.
Results: Most of our patients were menopausal (76.3%; mean age 55.7 years) and multiparous (mean parity 3.3) women. Urinary symptoms such
as urinary frequency, urgency, urge incontinence, and nocturia were decreased significantly ( p < 0.05). All urodynamic parameters did not
change significantly except for the maximum cystometric capacity ( p < 0.05), showing a significant increase after 3 months of medication.
Conclusions: Tolterodine, at a recommended dose, improves the symptoms of OAB syndrome without causing urine retention, as proved by the
changes of urodynamic parameters.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Overactive bladder (OAB) is a common chronic problem
that often requires long-term treatment to maintain control of
symptoms. OAB, as defined by the International Continence
Society, is a symptomatic diagnosis with urgency as the
cornerstone symptom, with or without urge incontinence, but
usually with urinary frequency and nocturia, in the absence of
other pathological or metabolic factors that may otherwise
cause similar symptoms [1]. OAB is a prevalent condition that
can affect all aspects of quality of life. Suffering individuals* Corresponding author. Department of Obstetrics and Gynecology, Kaoh-
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http://dx.doi.org/10.1016/j.tjog.2012.06.001have significant impairment of physical, social, emotional, and
sexual functions [2,3].
The age-adjusted prevalence of OAB is around 17% in
Taiwan as well as in the United States [4,5]. The prevalence of
OAB increases with age in both sexes and occurs in approx-
imately 30% in women over the age of 65 years [5]. The
pathophysiology is not yet understood fully and is thought to
be multifactorial. Nonsurgical treatment is the mainstay of
therapy for OAB, including biofeedback, bladder training,
electrical nerve stimulation, and medical treatment, or a
combination of these methods.
Antimuscarinic agents are the first-line medical treatment
for OAB symptoms and exert their effects on OAB by
blocking the muscarinic receptors on most structures in the
bladder wall (urothelium, lamina propria, and detrusor muscle)
[6]. Various antimuscarinic agents appear to have differentcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic characteristics of women (n ¼ 38) with over-
active bladder symptoms.
Mean age (years) 55.7  11.4
Mean parity 3.3  1.4
Mean BMI (kg/m2) 25.6  3.4
Menopause 29 (76.3)
Hormone therapy 6 (15.8)
Current smokers 5 (13.2)
Diabetes mellitus 5 (13.2)
Hypertension 11 (28.9)
History of hysterectomy 6 (15.8)
Data are presented as mean  SD or n (%).
BMI ¼ body mass index; POP ¼ pelvic organ prolapse;
SUI ¼ stress urinary incontinence; Sx ¼ surgery.
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oxybutynin are used more commonly. Tolterodine is a newer
drug designed specifically for treating OAB and has a rela-
tively lower incidence of side effects [8].
Several reports had demonstrated the efficacy and safety of
tolterodine in the treatment of OAB [7,8]. However, studies
concerning the changes in urodynamic parameters and clinical
symptoms after OAB treatment are limited [9,10]. Thus, the
purpose of this study was to investigate the changes of uro-
dynamic parameters and urinary symptoms after tolterodine
treatment in female OAB patients.
Materials and methods
Between November 2005 and March 2007, 47 consecutive
women visiting our outpatient clinic who underwent tolter-
odine (Detrusitol, Pfizer Inc., New York, USA) treatment for
OAB were reviewed retrospectively. The changes of urody-
namic parameters and subjective urinary symptoms after 3
months of treatment, as well as the demographic characteris-
tics, were collected and compared. Nine patients were
excluded from the study due to loss to follow-up, and
incomplete or uninterpretable data.
During the first visit, detailed personal history, pelvic ex-
amination, and urinalysis were performed. A personal inter-
view was also conducted for each woman with an OAB V8
questionnaire in order to identify the subjective urinary
symptoms. A scale of 0e5 (0 ¼ not at all, 1 ¼ a little bit,
2 ¼ somewhat, 3 ¼ quite a bit, 4 ¼ a great deal, and 5 ¼ a very
great deal) [11] was used to record the incidences of subjective
urinary symptoms. The diagnosis of OAB was made when the
patient answered “somewhat” or more to any one of the three
urge questions in the questionnaire (question 2, an uncom-
fortable urge to urinate; question 3, a sudden urge to urinate
with little or no warning; question 7, an uncontrollable urge to
urinate). In our recent report, translation of the OAB V8
questionnaire to Taiwanese has been validated for linguistic
accuracy [12]. Any obvious etiology (such as pregnancy,
genital organ prolapse, urinary tract infection, and any other
diseases or medications that possibly affect the lower urinary
tract functions) was excluded prior to the diagnosis of OAB.
All patients underwent a multichannel urodynamic study
prior to treatment according to a fixed protocol; this evaluation
was performed by the same experienced technician. The uro-
dynamic study was performed with a six-channel urodynamic
monitor (MMS; UD2000, Enschede, The Netherlands) ac-
cording to the recommendations by the International Conti-
nence Society [13]. The studies included spontaneous
uroflowmetry, both filling (at a rate of 50 mL/min with a 10F
Foley catheter) and voiding cystometry with infusion of
normal saline at room temperature, and urethral pressure
profilometry. Any uninhibited detrusor contraction during
filling cystometry was deemed positive for idiopathic detrusor
overactivity (DO).
Patients who were diagnosed with OAB were given anti-
muscarinic therapy with tolterodine (2 mg bid) for 3 months.
Post-treatment urodynamic study was then performed andinterpreted by the same observer to avoid any interobserver
bias; all patients were also asked to complete the questionnaire
again. All the data of urodynamic study and the OAB V8
questionnaire after 3 months of tolterodine treatment were
collected. Finally, nine women were excluded from the study
due to incomplete medical records or loss to follow-up.
This study protocol was reviewed and approved by the
Institutional Ethics Committee of our hospital. A statistical
analysis was performed using the paired t test for continuous
variables, and the McNemar or Chi-square test for categorical
variables. A difference was considered statistically significant
when p < 0.05.
Results
A total of 38 patients with complete data were included in
this study. Demographic characteristics of all patients are
shown in Table 1. The mean age was 55.7 years and mean
body mass index was 25.6. Twenty-nine of the 38 women
(76.3%) were menopaused and six (15.8%) were receiving
hormone replacement therapy.
Subjective changes of urinary symptoms are shown in
Table 2. Urinary symptoms, including urinary frequency, ur-
gency, nocturia, and urge incontinence, were improved
significantly after treatment ( p < 0.05). The percentage of
incomplete bladder emptying was increased nonsignificant.
The number of episodes of stress urinary incontinence and
urinary hesitancy did not differ significantly after treatment
( p > 0.05).
Comparisons of the urodynamic parameters prior to and
after treatment are shown in Table 3. Urodynamic stress in-
continence, maximum detrusor pressure, maximum flow rate,
residual urine, first sensation to void, detrusor pressure at peak
flow, functional urethral length, and maximum urethral closure
pressure did not differ significantly ( p > 0.05), comparing all
patients prior to and after the 3-month treatment of tolterodine.
The rate of DO decreased but did not reach a significant dif-
ference ( p ¼ 0.16). Only the maximum cystometric capacity
increased in a significant manner ( p ¼ 0.04). Seven patients
had residual urine >100 mL after treatment.
Comparisons of the subjective changes of urinary symptoms
between DO and non-DO patients are shown in Table 4. The
Table 2






Urinary frequency 38 (100) 15 (39.5) <0.01
Urgency 38 (100) 26 (68.4) <0.05
Stress urinary incontinence 32 (84.2) 29 (76.3) NS
Urge incontinence 24 (63.2) 14 (36.8) <0.05
Incomplete bladder emptying 11 (29.0) 13 (34.2) NS
Urinary hesitancy 3 (7.9) 2 (5.3) NS
Nocturia 29 (76.3) 15 (39.5) <0.05
Data are presented as n (%).
* McNemar’s test.
Tx ¼ treatment; NS ¼ not significant.
Table 4
Urinary symptoms in women with and without DO prior to and after 3 months
of medication.
DO (n ¼ 18) No DO (n ¼ 20)
Symptoms Pre-Tx Post-Tx p value* Pre-Tx Post-Tx p value*
Urinary
frequency
18 (100) 8 (44.4) <0.05 20 (100) 7 (35.0) <0.01
Urgency 18 (100) 10 (55.6) <0.05 20 (100) 16 (80.0) >0.05
SUI 17 (94.4) 15 (83.3) >0.05 15 (75.0) 14 (70.0) >0.05
Urge
incontinence
12 (66.7) 7 (38.9) >0.05 12 (60.0) 7 (35.0) >0.0.5
Incomplete
emptying
4 (22.2) 6 (33.3) >0.05 7 (35.0) 7 (35.0) >0.05
Urinary
hesitancy
1 (5.6) 1 (5.6) >0.05 2 (10.0) 1 (5.0) >0.05
Nocturia 11 (61.1) 7 (38.9) >0.05 18 (90.0) 8 (40.0) <0.01
* McNemar’s test.
Data are given as n (%).
DO ¼ detrusor overactivity; SUI ¼ stress urinary incontinence;
Tx ¼ treatment.
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significantly in both groups. Moreover, the symptoms of ur-
gency and nocturia were also improved in both groups; how-
ever, improvement in the symptom of urgency reached
significance only in the DO group and that of nocturia only in
the non-DO group. All the remaining symptoms were also
decreased nonsignificantly except for the symptom of incom-
plete bladder emptying, which was increased nonsignificantly
in the DO group and did not change in the non-DO group.
Discussion
Demographic data showed that the majority of our patients
were of advanced age (mean age 55.7 years), postmenopausal
(76.3%), and of greater parity (mean parity 3.3). These are
compatible with the etiologic risk factors of OAB in Taiwa-
nese women [14].
The subjective symptoms of urinary frequency, urge in-
continence, and nocturia improved significantly ( p < 0.05),
but the numbers of episodes of stress urinary incontinence,Table 3
Urodynamic changes prior to and after 3 months of medication.
Pre-Tx (n ¼ 38) Post-Tx (n ¼ 38) p value
Parameters
DO 18 (47.4) 15 (39.5) >0.05*
USI 26 (68.4) 24 (63.2) >0.05*
Qmax (mL/s) 19.7  8.6 19.9  12.4 >0.05**
RU (mL) 65.8  35.4 77.5  31.9 >0.05**
FS (mL) 145.1  74.4 147.3  80.9 >0.05**
MCC (mL) 311.1  140.0 354.2  122.2 <0.05**
Pdet (cmH2O) 26.7  17.7 26.0  16.8 >0.05**
MDP (cmH2O) 32.9  18.8 31.2  16.0 >0.05**
FUL (mm) 29.9  11.9 29.7  9.2 >0.05**
MUCP (cmH2O) 83.5  32.7 80.1  28.6 >0.05**
UCA (mm.cmH2O) 136.8  69.5 127.5  55.2 >0.05**
Data are presented as mean  SD or n (%).
*McNemar’s test.
**Paired t test.
DO ¼ detrusor overactivity; FS ¼ first sensation to void; FUL ¼ functional
urethral length; MCC ¼ maximum cystometric capacity; MDP ¼ maximum
detrusor pressure; MUCP ¼ maximum urethral closure pressure;
Pdet ¼ detrusor pressure at peak flow; Qmax ¼ maximum flow rate;
RU ¼ residual urine; Tx ¼ treatment; UCA ¼ urethra; closure;
USI ¼ urodynamic stress incontinence.incomplete bladder emptying, and urinary hesitancy did not
differ significantly after treatment. These results reflected the
pharmacologic effect of anticholinergic agents, taking into
account its small impact on stress urinary incontinence. The
symptom of urgency was improved nonsignificantly, which
may be attributed to the limited number of patients included in
the study.
The common view of the action of tolterodine in OAB
patients is that it acts by blocking competitively the musca-
rinic receptors on the detrusor muscle, which are stimulated by
acetylcholine released from activated parasympathetic nerves.
As a result, it inhibits the contractile ability of the bladder.
This blocking activity occurs mainly during the storage phase
of the bladder, increasing the total bladder capacity [15].
Several studies have shown a significant increase in the
bladder capacity after anticholinergic medication [9,10].
Therefore, the maximum bladder capacity has been suggested
to be a useful marker of the efficacy of treatment [16]. In this
study, a similar result was obtained, indicating the efficacy of
tolterodine in the treatment of OAB.
As mentioned above, tolterodine is a competitive antagonist
against muscarinic receptors; hence, although the concentra-
tion of acetylcholine is increased massively during the voiding
phase, the effect of tolterodine may be reduced. As expected,
no statistically significant changes were found in the urody-
namic parameters of voiding function, including maximum
flow rate, maximum detrusor pressure, and detrusor pressure at
peak flow.
Undoubtedly, blocking the contraction of the bladder may
also decrease the power of voiding and cause urine retention.
In our study, the mean volume of residual urine was increased
nonsignificantly ( p ¼ 0.33) after treatment. Seven patients had
residual urine >100 mL after treatment. Other authors also
reported similar results, showing no significant change in re-
sidual urine [9,10]. Therefore, the concern that tolterodine
may increase the risk of urine retention can be ignored in cases
of short-term use at normal dosage. Moreover, during this
study, no significant changes were observed in the maximum
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peak flow. Hsiao et al [17,18] also reported similar findings.
According to the above findings, tolterodine may not cause
clinically significant deterioration of voiding function, but
more attention should be paid to those women with large re-
sidual urine volume prior to treatment.
The rate of DO decreased nonsignificantly after treatment
(47.4% vs. 39.5%, p ¼ 0.16). Up to 50% of asymptomatic
women showed DO during ambulatory tests [19], which is
similar to our study. The detection rate of DO by urodynamic
study varies greatly, because a number of factors, including the
posture of the patient during the test, type of infusion medium
used, temperature of the medium, rate of infusion, and pro-
vocative tests used, cause detrusor contraction [20]. Thus, the
percentage of DO may not be a good predictor to evaluate the
efficacy of treatments, especially when the procedures of
urodynamic study were not standardized.
In general, the subjective urinary symptoms, including
urinary frequency, urgency, stress urinary incontinence, urge
incontinence, and nocturia, were improved. If we divide all the
patients into DO and non-DO groups, tolterodine was found to
be effective in improving the symptoms of frequency in both
groups, but it had greater impact on urgency in the DO group.
In addition, there was no change in urinary hesitancy and a
nonsignificant increase of incomplete bladder emptying in the
DO group, but no change in the non-DO group. Therefore,
tolterodine is not related to the deterioration of voiding
function. As mentioned above, the detection rate of DO by
urodynamic study may not be a good predictor to evaluate the
efficacy of treatments. Moreover, the limited number of pa-
tients enrolled may also cause bias.
The main limitation of this study is the small size of study
samples. Moreover, over 70% of patients had stress urinary
incontinence symptoms, indicating that most of the patients in
this study had mixed urinary incontinence, which may also be
a factor of influence. By contrast, a fixed protocol of urody-
namic examination, performed by the same experienced
technician and interpreted by the same observer, can avoid any
interobserver bias. Moreover, completion of the entire ques-
tionnaire by the patients themselves also minimized the bias
from other persons’ opinions.
Results of our study suggested that tolterodine improves the
symptoms of frequency, nocturia, and urge incontinence in
female OAB patients. Lack of changes in the urodynamic
parameters also revealed that anticholinergic agents had no
adverse effect on the voiding function. Moreover, a greater
impact on the therapeutic effects was observed in DO patients.
In conclusion, tolterodine, at a recommended dosage, is an
effective antimuscarinic agent for women with OAB, without
causing urinary retention.References
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